Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jespersen

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
American Heart Journal|July 29, 2014
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialErik Kjøller, Jørgen Hilden, Per Winkel, et al.
European Heart Journal|March 10, 2009
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery diseaseJens Kastrup, Julia S Johansen, Per Winkel, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 27, 2010
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trialMarina J Harutyunyan, Anders B Mathiasen, Per Winkel, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trialJørgen Hilden, Inga Lind, Hans Jørn Kolmos, et al.
BMJ (Clinical Research Ed.)|December 13, 2005
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialChristian M Jespersen, Bodil Als-Nielsen, Morten Damgaard, et al.
Journal of Cardiovascular Pharmacology|November 19, 2009
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart diseaseGorm B Jensen, Jørgen Hilden, Bodil Als-Nielsen, et al.
Cardiology|May 3, 2008
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart diseaseChristian Gluud, Bodil Als-Nielsen, Morten Damgaard, et al.
Journal of Virological Methods|May 24, 2017
Inactivation of West Nile virus in serum with heat, ionic detergent, and reducing agent for proteomic applicationsLouis A Altamura, Lisa H Cazares, Susan R Coyne, et al.
Science Immunology|March 27, 2021
A tumor-specific mechanism of T<sub>reg</sub> enrichment mediated by the integrin αvβ8Robert I Seed, Kenji Kobayashi, Saburo Ito, et al.
Science Translational Medicine|March 23, 2018
An OX40/OX40L interaction directs successful immunity to hepatitis B virusJean Publicover, Anuj Gaggar, Jillian M Jespersen, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
American Heart Journal|July 29, 2014
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialErik Kjøller, Jørgen Hilden, Per Winkel, et al.
European Heart Journal|March 10, 2009
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery diseaseJens Kastrup, Julia S Johansen, Per Winkel, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 27, 2010
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trialMarina J Harutyunyan, Anders B Mathiasen, Per Winkel, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trialJørgen Hilden, Inga Lind, Hans Jørn Kolmos, et al.
BMJ (Clinical Research Ed.)|December 13, 2005
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialChristian M Jespersen, Bodil Als-Nielsen, Morten Damgaard, et al.
Journal of Cardiovascular Pharmacology|November 19, 2009
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart diseaseGorm B Jensen, Jørgen Hilden, Bodil Als-Nielsen, et al.
Cardiology|May 3, 2008
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart diseaseChristian Gluud, Bodil Als-Nielsen, Morten Damgaard, et al.
Journal of Virological Methods|May 24, 2017
Inactivation of West Nile virus in serum with heat, ionic detergent, and reducing agent for proteomic applicationsLouis A Altamura, Lisa H Cazares, Susan R Coyne, et al.
Science Immunology|March 27, 2021
A tumor-specific mechanism of T<sub>reg</sub> enrichment mediated by the integrin αvβ8Robert I Seed, Kenji Kobayashi, Saburo Ito, et al.
Science Translational Medicine|March 23, 2018
An OX40/OX40L interaction directs successful immunity to hepatitis B virusJean Publicover, Anuj Gaggar, Jillian M Jespersen, et al.
Pageof 12